Here are five takeaways:
1. The program is designed to implement a value-based payment model for prescription drugs.
2. Democrats are concerned the new program will impact Medicare beneficiaries’ access to care and physician-administered drugs.
3. They caution CMS to consider the disruptions a new program may cause for patients with complex conditions.
4. CMS has said beneficiaries will have access to Part B medications. Also, CMS will analyze how the initiative would impact ongoing delivery and payment reform models.
5. CMS also seeks more stakeholder engagement before implementing the new program.
More articles on coding, billing & collections:
Nobilis Health creates bundled payment initiative — 5 key insights
ACOs to cover up to 176M patients by 2020 — 5 points
7 key insights into CMS’ MACRA
